Close Menu

In Just One Dose

MIT's Tech Review reports on Alnylam's RNAi-based drug that, with one dose, lowers cholesterol by up to 60 percent in rodents and monkeys. The drug targets PCSK9, an enzyme that had been shown to affect LDL levels and people's risk of heart disease. The RNAi drug was bundled into lipid-based nanoparticles to be transported to the liver once injected. This drug, says the article, could be used in conjunction with statins to get LDL levels even lower.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Howard Hughes Medical Institute will be requiring its researchers to publish their work so it is immediately accessible to the public, ScienceInsider writes.

The Huffington Post reports that Francis Collins, the director of the US National Institutes of Health, has urged Americans to recommit to reason.

About 150 million rapid coronavirus tests purchased by the US federal government are to be distributed to nursing homes, colleges, and the states, according to the New York Times.

In Nature this week: multi-omic analysis of Alzheimer's disease brain samples, de novo assembly of a diploid potato, and more.